Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation

Xenobiotica

Volumn 37, Issue 6, 2007, Pages 592-603

  Emoto, C ^a   Iwasaki, K ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

CYP2c19; CYP3a4; CYP3a5; Midazolam 1 hydroxylation

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM;

ARTICLE; CATALYSIS; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG METABOLISM; HYDROXYLATION; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PROTEIN FUNCTION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIDAZOLAM; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS;

EID: 34447121395     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701358749     Document Type: Article

References (26)

1. Emoto C, Iwasaki K. 2006. Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36:219-233.
2. Emoto C, Murase S, Iwasaki K. 2006. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36:671-683.
3. Houston JB, Kenworthy KE. 2000. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition 28:246-254.
4. Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL. 2005. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: Applications to drug metabolism. Journal of Chromatography B 822:27-32.
5. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. 1998. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring 20:243-247.
6. Krishna DR, Klotz U. 1994. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics Concepts 26:144-160.
7. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 62:162-172.
8. McGinnity DF, Parker AJ, Soars M, Riley RJ. 2000. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 28:1327-1334.
9. Mizutani T. 2003. PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism Reviews 35:99-106.
10. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. 1985. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 38:402-408.
11. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
12. Nordt SP, Clark RF. 1997. Midazolam: A review of therapeutic uses and toxicity. Journal of Emergency Medicine 15:357-365.
13. Obach R. S. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350-1359.
14. Rendic S. 2002. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 34:83-448.
15. Rodrigues AD. 1999. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology 57:465-480.
16. Rodrigues AD, Rushmore TH. 2002. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Current Drug Metabolism 3:289-309.
17. Soars MG, Gelboin HV, Krausz KW, Riley RJ. 2003. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 55:175-181.
18. Spatzenegger M, Jaeger W. 1995. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 27:397-417.
19. Streetman DS, Bertino, Jr, JS, Nafziger AN. 2000. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216.
20. Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. 2002. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzylphenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 30:235-239.
21. Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. 1996. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. Journal of Clinical Pharmacology 36:783-791.
22. Walsky RL, Obach RS. 2003. Verification of the selectivity of (+)-N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition 31:343.
23. Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 32:647-660.
24. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. 1999. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochemical and Biophysical Research Communications 259:201-205.
25. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. 2002. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition 30:883-891.
26. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. 2002. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metabolism and Disposition 30:1311-1319.